DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment

Information source: University of North Carolina, Chapel Hill
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Autism Spectrum Disorders

Intervention: Memantine-XR (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: University of North Carolina, Chapel Hill

Official(s) and/or principal investigator(s):
Linmarie Sikich, MD, Principal Investigator, Affiliation: University of North Carolina, Chapel Hill

Overall contact:
Lindsey M Hazzard, LCSW, Phone: 800-708-0048, Email: aspire@unc.edu

Summary

Specific Aim 1: Obtain proof of concept evidence that cortical metrics will change in response to treatment with Memantine extended release (XR), an agent that modulates n-methyl d-asptartate (NMDA) receptor activation, in children with autism spectrum disorders (ASD) who clinically demonstrate treatment response. Hypothesis1: Children with ASD who have dramatic clinical response to Memantine XR will exhibit changes in their cortical metrics, which will differ less from neurotypical children. Subjective ratings of improvement will be correlated with the change in cortical metrics. The completion of these aims will be essential to design a larger federally funded trial to validate cortical metrics as an outcome measure in a more heterogeneous pediatric ASD sample. Specifically, the feasibility data obtained may demonstrate the potential for detecting changes in cortical metrics over time, so that a larger grant could focus on determining how sensitive and clinically relevant changes in cortical metrics are or may indicate the need to explore different interventions to use in a validation study. We have chosen to use Memantine XR® because of its impact on NMDA neurotransmission, its current evaluation in a large multi-site randomized ASD clinical trial whose initial results are expected shortly, and our own observations of clinical improvements and good tolerability in the ongoing trial.

Clinical Details

Official title: Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: cortical metrics (a mathematical plot of tactile responsivity in 3 dimensions)

Secondary outcome:

Clinical Global Impressions - Improvement Score.

PDD-BI SV change 0-8

ABC-SW subscale score 0-8

Detailed description: Youth with ASD ages 8-12 years will undergo cortical metrics testing (testing of ability to discriminate the vibration of small brushes on the tops of the hand under various conditions) prior to treatment with memantine XR. They will then be treated with memantine XR target dose of 14milligrams daily for 8 weeks. At the end of 8 weeks, cortical metrics testing will be repeated. Within-subject changes in the cortical metrics testing between baseline and endpoint will be examined and described. Potential relationships between changes in clinical rating scales and cortical metrics will be examined. Data will be utilized to inform a decision about continuing to explore the utility of cortical metrics to detect changes in brain function in youth with ASD in response to therapeutic interventions.

Eligibility

Minimum age: 8 Years. Maximum age: 12 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Male Boys ages 8-12 with ASD (confirmed with ADOS-2 and DSM-5 checklist at screening)

- IQ's should be within the normal range (≥ 70) (by prior testing or Stanford-Binet 5

at screening)

- Primary caretaker is able to participate in study appointments as is clinically

indicated.

- Ability of child to participate in all aspects of the protocol per investigator

clinical judgment Exclusion Criteria:

- No new educational or behavioral intervention within 4 weeks of baseline.

- No history of non-febrile seizures, other neurological disorders, or comorbid

psychiatric disorders.

- Impairment of renal function

- Evidence or history of malignancy

- Any significant medical conditions including but not limited to hematological,

endocrine, respiratory, hepatic, cardiovascular or gastrointestinal disease

- Patients who, in the investigator's opinion, might not be suitable for the study

- Significant risk of suicidality based on investigator judgment

- History of hypersensitivity reaction to Memantine, dextromethorphan, amantadine or

any other NMDA antagonists

- Changes in psychotropic medications within 4 weeks of baseline visit

Locations and Contacts

Lindsey M Hazzard, LCSW, Phone: 800-708-0048, Email: aspire@unc.edu

Additional Information

Starting date: April 2015
Last updated: January 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017